Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.52 |
| ▸ | ACACA | Q13085 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289542 | 0.86 | ACACB (0.67) | ACACBACACA | |
| SCHEMBL4296840 | 0.84 | ACACB (0.68) | ACACBACACA | |
| SCHEMBL4305724 | 0.83 | ACACB (0.56) | ACACBACACAMAPK1 | |
| SCHEMBL4294128 | 0.83 | ACACB (0.52) | ACACBACACAKDM4EALDH1A1MEN1 | |
| SCHEMBL4296845 | 0.82 | ACACB (0.57) | ACACBACACAMAPK1 | |
| SCHEMBL976349 | 0.76 | ACACB (0.83) | ACACBACACA | |
| SCHEMBL2622325 | 0.76 | ACACB (0.83) | ACACBACACA | |
| SCHEMBL4295709 | 0.76 | ACACB (0.69) | ACACBACACAKDM4EALDH1A1MEN1 | |
| SCHEMBL6183505 | 0.75 | ACACB (0.84) | ACACBACACA | |
| SCHEMBL4298140 | 0.73 | ACACB (0.56) | ACACBACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
| EP-2009011-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281097-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TNNC1, CPT1B, TNNI3 | ACACB 23/4885ACACA 12/4885KDM4E 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.